TVM Capital Life Science

Egg Medical, Inc. is a medical device company based in Arden Hills, Minnesota, established in 2014. The company specializes in manufacturing healthcare equipment, with its flagship product being EGGNEST, a cath lab patient table designed to significantly reduce scatter radiation exposure for both patients and medical staff during procedures requiring real-time imaging. EGGNEST features a carbon fiber sled base which enhances safety without interrupting the workflow in cath labs. This innovative system also incorporates an integrated antimicrobial feature, providing additional protection for physicians, surgeons, nurses, and technicians. By prioritizing safety and efficiency, Egg Medical enables healthcare professionals to conduct critical diagnostic and therapeutic procedures effectively.

Neurocare is focused on enhancing mental health and performance through personalized therapy, guided by thorough assessments. The company develops integrated equipment solutions for neuroscience applications and operates a digital therapy platform that empowers clinicians to implement best practices in treatment. This platform is designed to deliver tailored programs by considering various factors such as brain activity, sleep patterns, biomarkers, and lifestyle metrics. By leveraging the principles of neuroplasticity, Neurocare aims to provide patients with measurable and effective clinical approaches, facilitating a customized pathway to improved mental well-being.

DEBx Medical is a pioneering medical technology company focused on advanced wound care solutions aimed at improving the quality of life for individuals with chronic wounds. The company specializes in addressing the challenges associated with hard-to-heal wounds, particularly in infection management and biofilm removal. DEBx Medical provides a comprehensive approach that encompasses diagnosis, treatment, follow-up care, and maintenance of healthy wound beds. By offering innovative and effective solutions, the company enables healthcare providers to enhance patient outcomes while delivering affordable and user-friendly treatments that can be easily integrated into everyday clinical practice.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through nanotechnology. The company develops a pipeline of next-generation nano-formulated drugs that improve the bioavailability of poorly water-soluble medications. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates either polymeric or crystalline nanoparticles designed to offer significant differentiation and added benefits for patients. In addition to its drug development efforts, the company provides services that support pre-clinical and clinical stage formulations for clients, including new chemical entities and established branded drugs. Through its innovative approach, Leon Nanodrugs aims to improve patient outcomes in the pharmaceutical industry.

Boston Oncology focuses on enhancing healthcare in emerging markets by developing and producing licensed biopharmaceutical products locally. The company provides essential resources and capital to enable these nations to manufacture and distribute specialty generic small-molecule and biotechnology therapies. By establishing local manufacturing facilities, Boston Oncology helps clients create and manage a portfolio of pharmaceutical products, facilitating access to specialty drugs, including oncology treatments, at reduced costs. This approach not only supports the health and prosperity of developing nations but also fosters regional self-sufficiency in healthcare.

Neurocare is focused on enhancing mental health and performance through personalized therapy, guided by thorough assessments. The company develops integrated equipment solutions for neuroscience applications and operates a digital therapy platform that empowers clinicians to implement best practices in treatment. This platform is designed to deliver tailored programs by considering various factors such as brain activity, sleep patterns, biomarkers, and lifestyle metrics. By leveraging the principles of neuroplasticity, Neurocare aims to provide patients with measurable and effective clinical approaches, facilitating a customized pathway to improved mental well-being.

Smart Reporting GmbH is a Munich-based company that specializes in providing a digital health solution for structured medical reporting, particularly in the fields of radiology and pathology. Established in 2014, the company offers an online platform that enables radiologists to generate high-quality medical reports through intelligent software that adheres to guideline-compliant criteria. The platform facilitates the creation of report templates, automatic text suggestions, and integration with hospital systems, thereby enhancing the efficiency and quality of medical reporting. Additionally, Smart Reporting provides tools for hospitals and practices to implement reporting standards, optimize templates, and ensure consistent report appearance across various physicians. The company also supports medical registries and clinical studies with solutions for structured reporting, data collection, and multilingual capabilities, all aimed at improving communication and quality assurance in medical documentation.

Vektor Medical, based in San Diego, focuses on transforming arrhythmia care for individuals suffering from atrial fibrillation and other related conditions. The company has developed an advanced, non-invasive technology called vMap, which utilizes artificial intelligence for the analysis and mapping of cardiac arrhythmias. This solution employs computational modeling alongside the patient's electrocardiogram to accurately identify sources of arrhythmias, including both focal and fibrillation types. Vektor Medical's FDA-cleared technology enhances the efficiency of cardiac ablation procedures, optimizes clinical workflows, and ultimately aims to improve patient outcomes in arrhythmia management.

Myo is a communication platform specifically developed for the elderly care market. It facilitates connections between elderly individuals and their families, enhancing communication through familiar messaging features. The platform allows caregivers to share various forms of content, including photos, videos, texts, and voice messages, ensuring that interactions are professional, secure, and direct. Myo aims to improve the overall care experience by fostering meaningful connections among caregivers, elderly individuals, and their relatives. The company is also focused on expanding its team with talented individuals dedicated to enhancing care solutions.

DEBx Medical is a pioneering medical technology company focused on advanced wound care solutions aimed at improving the quality of life for individuals with chronic wounds. The company specializes in addressing the challenges associated with hard-to-heal wounds, particularly in infection management and biofilm removal. DEBx Medical provides a comprehensive approach that encompasses diagnosis, treatment, follow-up care, and maintenance of healthy wound beds. By offering innovative and effective solutions, the company enables healthcare providers to enhance patient outcomes while delivering affordable and user-friendly treatments that can be easily integrated into everyday clinical practice.

Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.

Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers, has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours.

AMILI focuses on advancing gut microbiome research to address critical healthcare needs through the development of diagnostic tests, predictive algorithms, and microbiome-modifying interventions. The company collects gut microbiome stool samples to enhance its research and treatment capabilities, which aim to improve the health outcomes of patients suffering from infections and various diseases. Additionally, AMILI offers probiotics and conducts faecal microbiota transplants to support the treatment of bacterial infections. By utilizing its proprietary microbiome database, AMILI seeks to identify different types of gut microbiota, enabling medical professionals to leverage microbe science for better health management.

Egg Medical, Inc. is a medical device company based in Arden Hills, Minnesota, established in 2014. The company specializes in manufacturing healthcare equipment, with its flagship product being EGGNEST, a cath lab patient table designed to significantly reduce scatter radiation exposure for both patients and medical staff during procedures requiring real-time imaging. EGGNEST features a carbon fiber sled base which enhances safety without interrupting the workflow in cath labs. This innovative system also incorporates an integrated antimicrobial feature, providing additional protection for physicians, surgeons, nurses, and technicians. By prioritizing safety and efficiency, Egg Medical enables healthcare professionals to conduct critical diagnostic and therapeutic procedures effectively.

Centogene is a prominent genetic biotech company specializing in the diagnosis and analysis of rare inherited diseases. Headquartered in Rostock, Germany, with additional operations in Berlin and Cambridge, Massachusetts, Centogene focuses on transforming clinical, genetic, and biochemical data into actionable medical solutions. The company serves a diverse global patient population and aims to enhance awareness and understanding of rare diseases across various ethnicities. Centogene operates in two main segments: diagnostics, which offers targeted genetic sequencing and diagnostic services, and pharmaceuticals, which collaborates with partners to provide services such as patient recruitment, biomarker discovery, and epidemiological insights. Through its comprehensive approach, Centogene is dedicated to advancing the field of human genetics and improving the lives of patients and their families affected by rare diseases.

Access Vascular, Inc., founded in 2015 and based in Bedford, Massachusetts, specializes in the development of venous access devices that utilize innovative hydrogel materials to prevent thrombosis, infections, and other complications associated with intravenous therapy. The company’s portfolio includes a range of products such as peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. Access Vascular's technology aims to enhance clinical outcomes while reducing healthcare costs by minimizing the risk of blood clots and associated complications. Their flagship product, the HydroPICC, is designed to outperform existing technologies, potentially leading to shorter hospital stays and improved patient experiences. By addressing common challenges in venous access, Access Vascular seeks to improve the effectiveness and safety of intravenous treatments.

Kent Imaging Inc. is a medical device company based in Calgary, Canada, founded in 2006. The company specializes in the development and commercialization of multispectral oxygenation imaging technology aimed at improving patient outcomes in various medical fields, including plastic surgery, trauma care, wound management, and cardiac specialties. Kent Imaging's innovative imaging systems provide a non-invasive method for assessing tissue oxygen saturation, assisting physicians in evaluating compromised tissue without the need for contact or injected dyes. With multiple patents in medical technology, Kent Imaging is dedicated to delivering practical solutions that enhance decision-making in healthcare settings. In addition to its headquarters in Calgary, the company operates locations in Chicago, Los Angeles, Salt Lake City, and Seattle.

Vespina Lifesciences plans to develop to proof-of-concept a potential compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases. The compound was originally discovered and characterized at Denmark-based Neuprozyme Therapeutics ApS. There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis. There are no approved treatments that specifically address the underlying mechanism of disease.

ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and Crohn’s disease. The company's antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Tessier in Canada.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through nanotechnology. The company develops a pipeline of next-generation nano-formulated drugs that improve the bioavailability of poorly water-soluble medications. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates either polymeric or crystalline nanoparticles designed to offer significant differentiation and added benefits for patients. In addition to its drug development efforts, the company provides services that support pre-clinical and clinical stage formulations for clients, including new chemical entities and established branded drugs. Through its innovative approach, Leon Nanodrugs aims to improve patient outcomes in the pharmaceutical industry.

Emovi specializes in advanced knee joint assessment technologies aimed at improving patient quality of life. The company has developed a device that serves as a diagnostic aid for knee injuries and osteoarthritis, providing medical professionals with actionable data on joint movement while weight-bearing. This technology helps in reducing pain, minimizing opioid use, and shortening recovery times for patients. Emovi's commitment to innovation in healthcare is reflected in its focus on delivering high-quality products that enhance the treatment and management of knee conditions.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Founded in 2013 and headquartered in Newton, Massachusetts, the company has a diverse clinical pipeline that includes several promising candidates. EDSIVO is designed for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation. ACER-001, a taste-masked formulation of sodium phenylbutyrate, targets various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced vasomotor symptoms and has initiated research on emetine hydrochloride as a potential COVID-19 treatment in collaboration with the National Center for Advancing Translational Sciences. The company also holds a license agreement with Sanofi for worldwide rights to osanetant.

Panthera Dental Inc., founded in 2011 by brothers Gabriel and Bernard Robichaud, specializes in the design, development, manufacturing, and marketing of dental restoration solutions and dental sleep appliances. Based in Québec, Canada, with an additional office in New Jersey, the company offers a variety of products, including Angulated Screw Channels, Metal Implant Bars, and the Diamart two-part implant bridge, which enhances rigidity and supports cantilevers. Other notable products include the Integrated Bar for easy cleaning, the Lock 'n' Release Bar designed for patients with dexterity issues, and the D-SAD dental appliance for snoring treatment. Panthera Dental aims to improve patient quality of life through innovative and personalized implant systems and has established itself as a leader in the prosthetic implant market.

Centogene is a prominent genetic biotech company specializing in the diagnosis and analysis of rare inherited diseases. Headquartered in Rostock, Germany, with additional operations in Berlin and Cambridge, Massachusetts, Centogene focuses on transforming clinical, genetic, and biochemical data into actionable medical solutions. The company serves a diverse global patient population and aims to enhance awareness and understanding of rare diseases across various ethnicities. Centogene operates in two main segments: diagnostics, which offers targeted genetic sequencing and diagnostic services, and pharmaceuticals, which collaborates with partners to provide services such as patient recruitment, biomarker discovery, and epidemiological insights. Through its comprehensive approach, Centogene is dedicated to advancing the field of human genetics and improving the lives of patients and their families affected by rare diseases.

AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.

Ixchelsis Ltd is a clinical-stage biotechnology company based in Sandwich, United Kingdom, focusing on the development of an oxytocin receptor antagonist known as IX-01 for the treatment of premature ejaculation (PE). Founded in 2011, the company aims to establish IX-01 as a leading pharmacological option for PE. The drug has successfully completed a Phase 1 study involving healthy male volunteers and is advancing towards clinical proof of concept. Ixchelsis is supported by TVM Life Sciences Ventures VII and is led by a management team with significant expertise in pharmaceutical research and development, particularly in male sexual health. The company's initiatives are designed to provide innovative therapeutic solutions for male reproductive health issues.

AurKa Pharma is a biopharmaceutical company focused on developing a single compound aimed at treating solid tumors. The company has completed GLP toxicology studies and plans to initiate clinical development, pending regulatory approval. The primary objective is to demonstrate clinical proof-of-concept of efficacy in solid tumors, with the potential to explore additional cancer indications in the future. Through this targeted approach, AurKa Pharma aims to enhance treatment options for patients suffering from cancer.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Founded in 2013 and headquartered in Newton, Massachusetts, the company has a diverse clinical pipeline that includes several promising candidates. EDSIVO is designed for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation. ACER-001, a taste-masked formulation of sodium phenylbutyrate, targets various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced vasomotor symptoms and has initiated research on emetine hydrochloride as a potential COVID-19 treatment in collaboration with the National Center for Advancing Translational Sciences. The company also holds a license agreement with Sanofi for worldwide rights to osanetant.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through nanotechnology. The company develops a pipeline of next-generation nano-formulated drugs that improve the bioavailability of poorly water-soluble medications. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates either polymeric or crystalline nanoparticles designed to offer significant differentiation and added benefits for patients. In addition to its drug development efforts, the company provides services that support pre-clinical and clinical stage formulations for clients, including new chemical entities and established branded drugs. Through its innovative approach, Leon Nanodrugs aims to improve patient outcomes in the pharmaceutical industry.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Esperas Pharma is a special purpose company created to develop one compound to proof-of-concept.

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Definiens is a company that specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. Its software offers detailed insights from whole tissue slides, cell-based assays, and full-body scans, enabling users to correlate this information with data from various sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating new knowledge, thereby enhancing decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, Definiens aims to advance research fields, contribute to the development of personalized medicine, and improve patient quality of life. The company also maintains offices across the United States.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Invendo Medical GmbH specializes in the development, manufacturing, and distribution of sterile, single-use, and lightweight robotically-assisted endoscopy products aimed at gastroenterology and gastrointestinal surgery. The company's flagship product, the invendoscopy E200 System, comprises a sterile colonoscope, a handheld control body, and a supply and processing unit, designed to enhance the endoscopic experience for both patients and healthcare providers. Founded in 2001 and based in Weinheim, Germany, Invendo Medical strives to be a leader in the disposable endoscopy market by focusing on innovation that improves patient compliance and increases the number of procedures performed. The company serves healthcare facilities primarily in the United States and Europe and operates as a subsidiary of Ambu A/S since 2017.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Ixchelsis Ltd is a clinical-stage biotechnology company based in Sandwich, United Kingdom, focusing on the development of an oxytocin receptor antagonist known as IX-01 for the treatment of premature ejaculation (PE). Founded in 2011, the company aims to establish IX-01 as a leading pharmacological option for PE. The drug has successfully completed a Phase 1 study involving healthy male volunteers and is advancing towards clinical proof of concept. Ixchelsis is supported by TVM Life Sciences Ventures VII and is led by a management team with significant expertise in pharmaceutical research and development, particularly in male sexual health. The company's initiatives are designed to provide innovative therapeutic solutions for male reproductive health issues.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Definiens is a company that specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. Its software offers detailed insights from whole tissue slides, cell-based assays, and full-body scans, enabling users to correlate this information with data from various sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating new knowledge, thereby enhancing decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, Definiens aims to advance research fields, contribute to the development of personalized medicine, and improve patient quality of life. The company also maintains offices across the United States.

Manzil Healthcare Services specializes in delivering a wide range of individualized home care services aimed at enhancing the quality of life for patients. Their offerings include physiotherapy, elder care, mother and baby care, lactation consultation, and pediatric care, as well as specialized services like ventilation support and post-operative care. By providing technology-enabled, multidisciplinary care in the comfort of patients' homes, Manzil Healthcare Services supports both adult and pediatric patients in their health management needs, including wound care and diabetes management. This approach not only facilitates easier access to essential healthcare services but also fosters a supportive environment for recovery and well-being.

Cambridge Medical and Rehabilitation Center is a provider of post-acute care and rehabilitation services in the MENA region, focusing on patients with serious injuries or illnesses. The center aims to restore hope and ensure a continuum of care for both patients and their families. Utilizing modern technology alongside the expertise of physicians, physiotherapists, and speech and language pathologists, Cambridge Medical offers individualized treatment plans. Their range of services includes physical therapy, occupational therapy, speech-language therapy, hydrotherapy, and respiratory therapy. This comprehensive approach helps individuals with neurological issues to improve their health and achieve a level of independence, whether returning home on their own or with family support and home health services.

Amecath is a manufacturer and global distributor of medical products, specializing in catheter kits and supplies across urology, venous access, and dialysis. The company is involved in the design, development, and production of various types of catheters, including dialysis catheters, urological catheters, central venous catheters, pediatric catheters, and percutaneous sheath introducers. Amecath's products are protected by intellectual property rights and are sold in Egypt, as well as exported to multiple international markets.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

Anchor Therapeutics, Inc. is a biopharmaceutical company specializing in the design and development of peptide modulators for G protein-coupled receptors (GPCRs). The company focuses on creating Pepducin lipopeptide drug candidates that target the intracellular domains of GPCRs, allowing for allosteric modulation of GPCR signaling. Anchor Therapeutics aims to address various medical conditions, including cancer, inflammation, metabolic diseases, heart disease, and pain, through its innovative drug development platform. The company is engaged in pre-clinical research and offers internal programs targeting serious medical indications, such as diabetes and regenerative medicine. Originally incorporated as Ascent Therapeutics in 2006, the company rebranded to Anchor Therapeutics in 2010 and is located in Cambridge, Massachusetts.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Bourn Hall is a leading provider of fertility and in vitro fertilization services based in Cambridge, United Kingdom, with additional clinics in Colchester, Norwich, and Wickford. Established by IVF pioneers Steptoe and Edwards, Bourn Hall made history as the first clinic in the world to offer IVF treatments. The clinic caters to both self-funding and NHS patients, providing a safe and supportive environment to address fertility-related issues for both men and women. With a commitment to helping individuals and couples achieve their dreams of parenthood, Bourn Hall has successfully assisted in the conception of over 13,000 children, earning a reputation as a sanctuary for those facing difficulties conceiving.

Helomics Corporation is a personalized healthcare company focused on oncology, providing innovative tools to assist physicians and patients in making informed decisions throughout the cancer care continuum. It has developed a Precision Cellular Analytical Platform that analyzes cellular data over a 25-35 day period. Among its key products are ChemoFx, which aids in selecting effective treatments for gynecologic cancer patients; BioSpeciFx, offering biomarker tests for evaluating tumor responses at the molecular level; and GeneFx products, which use gene signatures to inform treatment options for colon and lung cancer patients. Additionally, Helomics provides tumor profiling services, including bioinformatics and patient-derived tumor models, which enhance clinical research and drug development. The company employs artificial intelligence through its D-CHIP platform to create personalized oncology roadmaps for patients. Founded in 1995 and headquartered in Pittsburgh, Pennsylvania, Helomics operates as a subsidiary of Predictive Oncology Inc.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

VPIsystems, formerly known as VPI Virtual Photonics, develops and markets network planning software and services for the telecommunications industry, both in the United States and internationally. The company offers products such as Photonic Design Automation, which models and optimizes photonic components, and OnePlan, an integrated system that assists communications service providers, systems integrators, and manufacturers in transitioning to IP-based networks. VPIsystems aims to enhance the efficiency of network planning and engineering processes through predictive network analytics, enabling clients to optimize network integration and improve overall network reliability. The company serves a diverse clientele, including wireline and wireless carriers, broadband providers, and equipment manufacturers. Founded in 1997, VPIsystems is headquartered in Holmdel, New Jersey, with additional offices in Europe, Asia, and Australia, and maintains strategic alliances with notable firms such as Accenture and HP.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

ProVita International Medical Center, based in Abu Dhabi, United Arab Emirates, operates healthcare facilities that specialize in post-acute care and rehabilitation services. Founded in 1995, ProVita provides a wide range of services, including nursing, respiratory therapy, physiotherapy, occupational therapy, speech therapy, and nutritional services, catering particularly to ventilator-dependent residents. The center is notable for its multicultural environment, employing around 300 internationally trained staff who adhere to high global nursing standards, ensuring comprehensive care for patients. ProVita has established itself as a leader in providing patient-centric care, contributing to its reputation as a pioneering facility in the region.

Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Arteris is a prominent provider of system IP that specializes in accelerating system-on-chip (SoC) development for various electronic systems. The company focuses on network-on-chip (NoC) interconnect technology and offers automation software for SoC integration, which enhances product performance while reducing power consumption and time to market. Arteris' solutions enable customers to efficiently implement NoC IP, along with providing ongoing support, maintenance, professional services, and training. With operations spanning the Americas, Asia Pacific, and Europe, the company derives a significant portion of its revenue from the Asia Pacific region, positioning itself as a key player in the semiconductor industry.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Ubidyne, established in 2005, specializes in digital active antenna technology, specifically its innovative Antenna Embedded Radio™ system. This technology is designed to enhance mobile communication by integrating micro-radio technology directly within wireless antennas. Ubidyne's products, which are offered through collaboration with Nokia Siemens Networks, support a range of standards including GSM, UMTS, HSPA+, and LTE. The company's integrated active antenna systems are compatible with CPRI and OBSAI optical interfaces, allowing for advanced multi-standard wireless services that cater to various applications, from pico cells to large-scale macro cells and distributed in-building systems. By eliminating the need for coaxial feeder cables, remote electrical tilt, and additional amplifiers, Ubidyne's solutions significantly reduce energy consumption while improving radio performance, deployment flexibility, coverage, and capacity of mobile networks globally.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

ExtendMedia specializes in software and media services that assist content providers and distributors in creating, delivering, managing, and monetizing online content across various devices. The company's flagship product, OpenCASE, serves as a robust foundation for digital media businesses, enabling efficient integration with existing systems and automating large-scale content delivery processes. With over 16 years of experience, ExtendMedia has collaborated with leading communications and media companies, embedding its extensive industry knowledge into OpenCASE. This software not only enhances operational efficiency but also supports diverse business models, making it a valuable tool for media companies and network operators managing digital video content.

Silicon Hive BV is a company that specializes in semiconductor intellectual property, providing a range of solutions including processor cores, program development tools, and application libraries. Founded in 2003 and based in Eindhoven, the Netherlands, with additional offices in San Jose, Tokyo, Seoul, and Bangalore, Silicon Hive designs, builds, and licenses application-specific systems primarily for semiconductor manufacturers and original equipment manufacturers. Its products enable the creation of programmable integrated circuits tailored for imaging, video, and wireless communication applications. The company's innovative solutions and parallel processor technologies are integral to the functionality of camera systems, video systems, and wireless communications, allowing clients in the consumer electronics sector to enhance their offerings. Silicon Hive has been operating independently since April 2007.

CommProve specializes in real-time Quality of Service (QoS) monitoring for wireless networks, having been established in 1996 by experts in network operations and software engineering. The company focuses on developing software that allows wireless operators to monitor and enhance their network performance and subscriber experience. Its platform facilitates real-time data acquisition and analysis, collecting information from both analogue and LTE mobile networks. By integrating this data with business rules and subscriber information, CommProve enables mobile network operators to gain insights into their operations, thereby improving financial performance and ensuring a high-quality user experience. The company's initial engagements with Tier 1 customers highlighted the necessity for effective measurement and reporting of subscriber experience through the radio link.

SpePharm is a European specialty pharmaceutical company focused on acquiring, registering, and marketing high-value medicines primarily for the hospital market. The company specializes in oncology, hematology, and supportive care, offering medical products that assist clinicians in managing oral complications associated with radiotherapy or chemotherapy. SpePharm's management team possesses extensive global experience in the pharmaceutical sector, particularly with a deep understanding of the European regulatory landscape and the nuances of niche and orphan products. Their expertise allows them to implement innovative strategies and achieve notable successes in the field.

Since its inception, BitWave has been dedicated to the development of a universal programmable transceiver, the Softransceiver RFIC. The technology will allow wireless carriers and cell phone manufacturers to deploy more services and devices in less time with additional functionality.

Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

Arteris is a prominent provider of system IP that specializes in accelerating system-on-chip (SoC) development for various electronic systems. The company focuses on network-on-chip (NoC) interconnect technology and offers automation software for SoC integration, which enhances product performance while reducing power consumption and time to market. Arteris' solutions enable customers to efficiently implement NoC IP, along with providing ongoing support, maintenance, professional services, and training. With operations spanning the Americas, Asia Pacific, and Europe, the company derives a significant portion of its revenue from the Asia Pacific region, positioning itself as a key player in the semiconductor industry.

Winbox Technologies specializes in connected-TV solutions tailored for original equipment manufacturers and service providers. The company offers a range of hardware and software products designed to streamline the development of IPTV receivers, video-on-demand systems, hard disk video recorders, connected TVs, and set-top boxes. By utilizing Winbox Technologies' offerings, customers can reduce both development time and investment costs. The company provides complete "TurnKey" solutions that encompass hardware, software, and production services, as well as the option to license specific technology modules for in-house development. This enables clients to enhance their operational efficiency and accelerate time-to-market for their connected-TV products.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

CoreOptics specializes in providing advanced solutions for high-speed optical networking applications within the telecommunications and information technology sectors. The company is recognized for its 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, which are essential for Metro, Regional, and Long Haul optical and data networks. CoreOptics advocates for open optical communication systems that can efficiently transmit data across various rates and fiber types. Its innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is notable for enabling Tier 1 systems vendors and carriers to enhance network performance without overhauling existing fiber infrastructure. By eliminating the need for Optical Compensators and Second Stage Amplifiers, CoreOptics' products can significantly lower first-in deployment costs for customers, achieving reductions of up to 30%.

Albireo Pharma, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative bile acid modulators aimed at treating rare pediatric liver diseases and gastrointestinal disorders. The company's lead product candidate, odevixibat, is an ileal bile acid transporter inhibitor currently undergoing phase III clinical trials for the treatment of progressive familial intrahepatic cholestasis, biliary atresia, alagille syndrome, and other cholestatic liver diseases. Additionally, Albireo is advancing Elobixibat, which targets chronic constipation and other functional gastrointestinal disorders, as well as nonalcoholic steatohepatitis. The company is also developing A3384 for gastrointestinal diseases and has established a licensing agreement with EA Pharma for the development and commercialization of elobixibat.

RIEMSER Pharma GmbH, based in Greifswald, is an international specialty pharmaceutical company dedicated to addressing high unmet medical needs in therapeutic niche areas. The company specializes in the distribution and life cycle management of pharmaceuticals, with core competencies in oncology, anti-infectives, and dermatology. With a strong emphasis on innovation and patient care, RIEMSER Pharma leverages its extensive expertise to enhance the availability and effectiveness of its products in these critical therapeutic fields.

Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

Enigma Semiconductor develops advanced silicon solutions aimed at enhancing wired communications. The company focuses on creating innovative components and subsystems for various applications, including metropolitan and access networks, enterprise and internet infrastructure, and storage systems. Enigma offers semiconductors for switching systems, line card, and backplane systems, supporting link speeds of up to 6.25G and line card speeds of up to 1x40G. The management team comprises experienced professionals with backgrounds in prominent technology firms, ensuring a strong foundation for the company's growth and innovation in the semiconductor industry.

Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.

Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Arteris is a prominent provider of system IP that specializes in accelerating system-on-chip (SoC) development for various electronic systems. The company focuses on network-on-chip (NoC) interconnect technology and offers automation software for SoC integration, which enhances product performance while reducing power consumption and time to market. Arteris' solutions enable customers to efficiently implement NoC IP, along with providing ongoing support, maintenance, professional services, and training. With operations spanning the Americas, Asia Pacific, and Europe, the company derives a significant portion of its revenue from the Asia Pacific region, positioning itself as a key player in the semiconductor industry.

Netviewer GmbH specializes in web conferencing solutions, enabling users to collaboratively view and edit documents online. Founded in 2001 and headquartered in Karlsruhe, Germany, the company offers a range of products, including Netviewer Meet for internet meetings, Netviewer Support for customer assistance, and Netviewer Admin for administrative tasks. Additional offerings include Netviewer Present for online meetings, educational webinars, and conventions. These services are available as software-as-a-service, catering to various applications such as project collaborations, live demonstrations, and training sessions. Netviewer also has subsidiary operations in multiple countries, including Switzerland, France, the United Kingdom, the United States, the Netherlands, Austria, Italy, Spain, Poland, and Sweden.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Silicon Hive BV is a company that specializes in semiconductor intellectual property, providing a range of solutions including processor cores, program development tools, and application libraries. Founded in 2003 and based in Eindhoven, the Netherlands, with additional offices in San Jose, Tokyo, Seoul, and Bangalore, Silicon Hive designs, builds, and licenses application-specific systems primarily for semiconductor manufacturers and original equipment manufacturers. Its products enable the creation of programmable integrated circuits tailored for imaging, video, and wireless communication applications. The company's innovative solutions and parallel processor technologies are integral to the functionality of camera systems, video systems, and wireless communications, allowing clients in the consumer electronics sector to enhance their offerings. Silicon Hive has been operating independently since April 2007.

ExtendMedia specializes in software and media services that assist content providers and distributors in creating, delivering, managing, and monetizing online content across various devices. The company's flagship product, OpenCASE, serves as a robust foundation for digital media businesses, enabling efficient integration with existing systems and automating large-scale content delivery processes. With over 16 years of experience, ExtendMedia has collaborated with leading communications and media companies, embedding its extensive industry knowledge into OpenCASE. This software not only enhances operational efficiency but also supports diverse business models, making it a valuable tool for media companies and network operators managing digital video content.

Azea Networks Limited, provides world-class submarine optical networking solutions Azea Networks provides world-class submarine optical networking solutions that allow operators to exploit the full potential of their existing cable assets. Azea is uniquely focused on delivering substantial, and cost effective, capacity gains over existing undersea systems. The Azea team combines extensive optical engineering experience in characterisation, system design, modelling and product implementation to provide technologies and services that are a compelling alternative to the cost and risk of deploying new submarine cable systems. Azea’s head office is in London, with manufacturing in Scotland and a number of regional support offices.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

Hymite is a venture funded product company bringing to market the next generation packaging platform for use with High Power (HP) / Ultra-high Brightness (UHB) LEDs. Hymite's Engineered Silicon (Si) package platform delivers new levels of performance and value to their customers developing products for Solid State Lighting applications.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.